Liquid Biopsy in Hematologic Malignancies: Current Evidence and Clinical Applications

Abstract

Liquid biopsy represents a transformative approach to the diagnosis and management of hematologic malignancies, offering a minimally invasive method to analyze tumor-derived genetic material from peripheral blood. This review comprehensively evaluates the current status, mechanisms, clinical applicability, and future directions of liquid biopsy in leukemia, lymphoma, and multiple myeloma. Emphasis is placed on the interpretation of circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and circulating tumor cells (CTCs), alongside their diagnostic, prognostic, and therapeutic implications. Recent evidence demonstrates the utility of liquid biopsy in disease monitoring, treatment stratification, and early detection of relapse, with emerging data supporting integration into clinical practice and guidelines. Challenges, including standardization, sensitivity, and specificity, are critically discussed to outline the real-world benefits and limitations for clinicians.

Introduction

Hematologic malignancies, encompassing diverse disorders such as leukemia, lymphoma, and multiple myeloma, present significant diagnostic and therapeutic challenges. Traditional tissue-based biopsies, though pivotal, are invasive, associated with procedural risks, and often fail to capture tumor heterogeneity or dynamic changes over time. Liquid biopsy, defined as the analysis of tumor-derived components in peripheral blood or other body fluids, has emerged as a minimally invasive diagnostic tool. Its applications range from early detection and molecular profiling to minimal residual disease (MRD) assessment and monitoring for relapse. Driven by technological advances in next-generation sequencing (NGS) and digital PCR, liquid biopsy is reshaping the management of hematologic cancers, offering the promise of personalized and adaptive therapy.

Epidemiology / Disease Burden

Globally, hematologic malignancies account for a substantial proportion of cancer morbidity and mortality, with rising incidence reported in both developed and developing regions. Leukemias, lymphomas, and plasma cell neoplasms collectively contribute to millions of new cases annually. Timely diagnosis and risk-adapted management are crucial, yet conventional diagnostic modalities often fall short in capturing disease complexity. The need for repeated sampling to monitor disease status further compounds the clinical burden. Liquid biopsy offers an avenue to overcome these epidemiological challenges by facilitating repeated, real-time molecular assessments, thus potentially improving patient outcomes and resource utilization in both high- and low-prevalence settings.

Pathophysiology

Hematologic malignancies are characterized by clonal proliferation of aberrant hematopoietic cells, resulting from genetic and epigenetic alterations. As malignant cells proliferate, they release nucleic acids (ctDNA, cfDNA), exosomes, and intact cells (CTCs) into the circulation. These circulating biomarkers reflect the molecular heterogeneity and clonal evolution of the tumor. Mechanistically, the release of ctDNA correlates with tumor burden, apoptosis, and necrosis, while CTCs serve as direct representatives of malignant clones. Liquid biopsy leverages these biological processes to provide a real-time snapshot of the tumor’s genetic landscape, including actionable mutations and resistance mechanisms.

Risk Factors

Risk factors for hematologic malignancies are multifactorial, encompassing genetic predisposition, environmental exposures, immune dysregulation, and prior cytotoxic therapies. For liquid biopsy, additional risk factors influence the efficacy and interpretation of results, such as tumor burden, disease localization, and the integrity of the blood-tumor barrier. In cases of low disease burden or sanctuary sites (e.g., CNS lymphomas), the sensitivity of liquid biopsy may be reduced, underscoring the importance of context-specific application and validation. Ongoing research aims to refine pre-analytical and analytical variables to optimize liquid biopsy performance across risk strata.

Clinical Features

Patients with hematologic malignancies often present with nonspecific symptoms fatigue, fever, weight loss, lymphadenopathy, cytopenias necessitating thorough diagnostic evaluation. While traditional approaches rely on peripheral blood counts, bone marrow examination, and tissue biopsy, liquid biopsy offers a complementary modality. Clinically, the detection of ctDNA or CTCs can precede overt hematologic relapse or morphologic changes, providing an early warning signal for intervention. Serial monitoring enables dynamic risk stratification, guiding the timing and intensity of therapeutic interventions in both symptomatic and asymptomatic patients.

Diagnosis

Liquid biopsy enhances the diagnostic algorithm for hematologic malignancies by enabling noninvasive genomic profiling. Techniques include NGS for mutation detection (e.g., FLT3, NPM1 in AML; IGH rearrangements in lymphomas), digital PCR for quantifying MRD, and flow cytometry for CTC enumeration. Liquid biopsies can identify actionable mutations, track clonal evolution, and distinguish between malignant and benign clonal hematopoiesis. However, sensitivity and specificity may vary depending on disease type, burden, and technical factors. Integration with conventional diagnostics remains essential, with liquid biopsy serving as an adjunct to, rather than a replacement for, established methods.

Treatment & Management

The advent of liquid biopsy enables personalized therapy by informing prognosis, predicting response, and guiding therapy selection. For instance, in acute leukemia, dynamic changes in ctDNA can indicate response to induction chemotherapy and predict MRD status, guiding consolidation or intensification strategies. In lymphomas and myeloma, detection of resistance mutations (e.g., BTK, BCL2, or proteasome inhibitors) informs therapeutic switching and clinical trial eligibility. Longitudinal monitoring via liquid biopsy supports adaptive management, potentially enabling earlier intervention upon molecular relapse and minimizing overtreatment in deep responders.

Recent Advances / Emerging Therapies

Recent years have witnessed remarkable advances in liquid biopsy technologies, including ultrasensitive NGS platforms, integration of multi-omics (proteomics, metabolomics), and machine learning algorithms for data interpretation. Digital droplet PCR and error-corrected NGS achieve detection limits as low as 0.01% variant allele frequency, enhancing MRD monitoring. Emerging applications include cell-free RNA analysis and exosome profiling for deeper phenotyping. Clinical trials increasingly incorporate liquid biopsy endpoints for patient stratification and real-time therapeutic adjustment, paving the way for precision oncology in hematologic malignancies.

Guideline Recommendations

Major hematology societies now recognize the potential role of liquid biopsy in disease monitoring and MRD assessment. The European LeukemiaNet, NCCN, and ESMO recommend consideration of liquid biopsy-based MRD testing, particularly in patients where bone marrow biopsy is contraindicated or serial sampling is required. However, guidelines emphasize the need for standardized assays, validation in prospective trials, and integration with clinical and laboratory parameters. Consensus statements highlight the current role of liquid biopsy as a supplement to conventional diagnostics, pending further evidence to support broader adoption.

Conclusion

Liquid biopsy is redefining the landscape of hematologic malignancy management by facilitating noninvasive, real-time molecular assessment. Its utility spans diagnosis, prognostication, treatment guidance, and relapse monitoring, with growing evidence supporting its integration into clinical workflows. While challenges remain particularly in assay standardization and interpretation ongoing research and collaborative initiatives are poised to address these gaps. As technology evolves and evidence accumulates, liquid biopsy is expected to become an indispensable tool in the precision management of hematologic cancers, ultimately improving patient outcomes and quality of care.